Connect with us

Technology

In-Vitro and In-Vivo Micro Electrode Array Market to Grow by USD 7 Million (2024-2028), Driven by MEA Applications in Neuroscience Research, with AI Driving Market Transformation – Technavio

Published

on

NEW YORK, Dec. 3, 2024 /PRNewswire/ — Report with the AI impact on market trends – The global in-vitro and in-vivo micro electrode array market size is estimated to grow by USD 7 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of about 4.3% during the forecast period. Extensive use of meas in neuroscience research is driving market growth, with a trend towards potential application of in-vitro and in-vivo mea in cancer tissue detection. However, limitations of meas poses a challenge. Key market players include 3Brain AG, Alpha Omega Engineering Ltd., Axion BioSystems Inc., Blackrock Microsystems Inc., Cambridge NeuroTech, FHC Inc., Harvard Bioscience Inc., IMEC Inc., Innovative Neurophysiology Inc., MaxWell Biosystems AG, Microprobes for Life Science, MICRUX FLUIDIC S.L., NeuroNexus Technologies Inc., NMI Technologie Transfer GmbH, Plexon Inc., Ripple Neuro, Screen Holdings Co. Ltd, SpikeGadgets, Tucker Davis Technologies, and World Precision Instruments.

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

In-Vitro And In-Vivo Micro Electrode Array Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 4.3%

Market growth 2024-2028

USD 7 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

4.0

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 58%

Key countries

US, UK, Germany, France, and Japan

Key companies profiled

3Brain AG, Alpha Omega Engineering Ltd., Axion BioSystems Inc., Blackrock Microsystems Inc., Cambridge NeuroTech, FHC Inc., Harvard Bioscience Inc., IMEC Inc., Innovative Neurophysiology Inc., MaxWell Biosystems AG, Microprobes for Life Science, MICRUX FLUIDIC S.L., NeuroNexus Technologies Inc., NMI Technologie Transfer GmbH, Plexon Inc., Ripple Neuro, Screen Holdings Co. Ltd, SpikeGadgets, Tucker Davis Technologies, and World Precision Instruments

Market Driver

The In-vitro and In-vivo Micro Electrode Array (MEA) market is experiencing significant growth due to increasing research in neurological disorders and cancer tissue detection. MEAs, also known as Micro Electrode Arrays, are essential tools for recording neural activity and measuring brain function. The market includes both Multiwell MEAs and Single well MEAs, with CMOS-based MEAs gaining popularity for their cost-effectiveness and high-density electrodes. Key players in the market include Pharmaceutical and Biotech companies, Contract Research Organizations (CROs), and government research labs. Trends include the development of Neurostimulation devices, Diagnostic Solutions, and Therapeutic Solutions using MEAs. New technologies like 3D nanoparticle printing, Graphene-based Electrodes, and Flexible Electrodes are enhancing MEA capabilities. Neuroengineering applications, such as Brain-Computer Interfaces, Deep Brain Stimulation, and Synaptic Connections, are also driving market growth. Biocompatibility and signal quality remain crucial factors, with advancements in microfabrication techniques like Photolithography and 3D Printing addressing these challenges. The market encompasses applications in Clinical Settings, Drug Development, Disease Modeling, Neuroprosthetics, and Brain-Computer Interfaces. Personalized Medicine and Wireless Recording Technologies are emerging trends, offering opportunities for Drug Candidates and improving research efficiency. 

The global market for In-Vitro and In-Vivo Micro Electrode Arrays (MEAs) is witnessing significant growth due to the increasing focus on early cancer detection. Researchers and oncologists are exploring the integration of MEA technology with micro-needle arrays to monitor the electrical impedance of cancer tissue. This approach aims to study the electrical properties of various cancer cells and tissue cultures, offering potential for more accurate and patient-friendly cancer diagnosis. The market’s growth is driven by the high mortality rate of cancer and the need for advanced diagnostic tools. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

The In-vitro and In-vivo Micro Electrode Array (MEA) market is gaining significant traction in the biotech and pharmaceutical industries. MEAs, which include Micro Electrode Arrays and CMOS-based MEAs, play a crucial role in understanding neural activity and brain function for neurological disorders. In-vivo MEAs enable the recording of electrical signals from neurons in living organisms, while in-vitro MEAs are used for lab-grown neuronal networks. Challenges in this market include cancer tissue detection, biocompatibility, signal quality, and high-density electrodes. Technological advancements such as 3D nanoparticle printing, flexible electrodes, and graphene-based electrodes are addressing these challenges. Neurostimulation devices, drug development, disease modeling, and brain-computer interfaces are key applications for MEAs in clinical settings. CROs, government research labs, and Precision Instruments are major players in this market. Multiwell and single well MEAs, photolithography, and 3D printing are essential microfabrication techniques. Wireless recording technologies and personalized medicine are future growth areas.In-Vitro and In-Vivo Micro Electrode Arrays (MEAs) are widely used in research for studying neural activity. Advanced MEAs, such as in vitro CMO-based HDMEAs, are popular due to their capabilities. However, in vitro MEAs have limitations. They lack the high spatial resolution needed for stimulating and recording single cells, making them less suitable than dynamic clamp and patch clamp systems. Furthermore, MEA implantation, particularly chronic implantation, can result in biological responses like a decrease in functioning electrodes, glial scarring, and neuronal cell loss. These responses depend on factors such as MEA shank sizes, inter-shank distances, material composition, and implantation duration. Despite these challenges, MEAs remain a valuable tool for neuroscience research.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview

This in-vitro and in-vivo micro electrode array market report extensively covers market segmentation by

End-user 1.1 Pharmaceutical companies and CROs1.2 Academic/government and other research labsType 2.1 Multiwell MEA2.2 Single well MEAGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Pharmaceutical companies and CROs- The pharmaceutical and biotechnology industry and Contract Research Organizations (CROs) have increasingly adopted Micro Electrode Array (MEA) systems for neuroscience research. MEAs enable precise phenotypic drug screening while retaining neuronal functionality. CROs offer reduced costs and access to advanced equipment for pharmaceutical and biotechnology companies, making outsourcing an attractive option. MEAs are utilized for various research activities, from basic research to late-stage development, including genetic engineering, safety and efficacy tests, assay development, target validation, and clinical trials. Sanofi AG, Boehringer Ingelheim Pharma GmbH and Co. KG, and Janssen Pharmaceutica NV are among the companies employing MEAs for epilepsy research, cardiac safety assessment, and drug identification, respectively. The growing adoption of MEAs by these industry players is expected to fuel the expansion of the global in-vitro and in-vivo MEA market during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

In-vitro Micro Electrode Arrays (MEAs), also known as Micro Electrode Arrays, are a valuable tool in various research fields, including neuroscience and cancer tissue detection. MEAs consist of an array of electrodes that can record electrical signals from living cells or tissues. Neuroscience researchers use MEAs to study neural activity, brain function, and neuroengineering. In the biotech and pharmaceutical industries, MEAs are employed for therapeutic solutions, such as neurostimulation devices. MEAs come in different formats, including Multiwell and Single well arrays. The latest advancements in MEA technology include CMOS-based MEAs and 3D nanoparticle printing. These innovations offer improved sensitivity, accuracy, and miniaturization, making MEAs an essential diagnostic and therapeutic solution for the future. In-Vitro Microelectrode Arrays provide valuable insights into electrical signals from living cells and tissues, contributing significantly to research and development in various industries.

Market Research Overview

In-vivo Micro Electrode Arrays (MEAs), also known as Micro Electrode Arrays for Neuroscience applications, are advanced technological tools used for recording neural activity and stimulating brain tissue in real-time. MEAs find extensive applications in various fields, including neurological disorders research, drug development, disease modeling, neuroengineering, and brain-computer interfaces. In-vivo MEAs can be fabricated using different materials such as CMOS, graphene, or flexible electrodes, using microfabrication techniques like photolithography and 3D printing. These arrays offer high-density electrodes, enabling the recording of electrical signals from a large number of neurons, neural networks, and synaptic connections. In vitro MEAs are used for diagnostic solutions, while in vivo MEAs are employed in therapeutic applications like neurostimulation devices, deep brain stimulation, and neural prosthetics. MEAs have significant potential in personalized medicine, allowing for the detection of drug candidates and monitoring brain function in clinical settings. Wireless recording technologies are also being explored to enhance the versatility of MEAs. In summary, MEAs play a crucial role in understanding brain function, developing new therapies, and advancing our knowledge of brain-related disorders.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

End-userPharmaceutical Companies And CROsAcademic/government And Other Research LabsTypeMultiwell MEASingle Well MEAGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/in-vitro-and-in-vivo-micro-electrode-array-market-to-grow-by-usd-7-million-2024-2028-driven-by-mea-applications-in-neuroscience-research-with-ai-driving-market-transformation—technavio-302319761.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

AiRISTA Launches Newest Version of Sofia™, Setting a Standard for Enterprise-Grade Real-Time Location Systems

Published

on

By

Platform modernization delivers unmatched flexibility, enterprise security, and open interoperability — reinforcing AiRISTA’s position as the RTLS platform built to scale with any technology environment

TIMONIUM, Md., July 21, 2026 /PRNewswire/ — AiRISTA, a leading provider of real-time location systems (RTLS) trusted by more than 300 organizations worldwide, today announced the newest release of its flagship Sofia™ real-time location intelligence platform. Building on the foundation established with the Vision RTLS platform, Sofia represents the next evolution of AiRISTA’s location intelligence platform to meet the evolving needs of enterprise and government customers.

As organizations increasingly rely on location intelligence to improve staff safety, operational efficiency, and workflow automation, Sofia enables them to leverage existing technology investments through an open, technology-agnostic platform rather than a single-vendor ecosystem.

Sy Sajjad, Founder and CEO, AiRISTA: “Sofia reflects what we’ve believed since founding AiRISTA: location intelligence should adapt to how an organization actually operates, not force the organization to adapt to a single vendor’s technology. With this release, we’ve strengthened the security, flexibility, and scalability that enterprise and healthcare customers require — while staying true to the open, technology-agnostic architecture that has always set Sofia apart.”

Key enhancements in the new release include:

A modernized user experience with simplified administration

Enterprise-grade security with Single Sign-On (SSO), Multi-Factor Authentication (MFA), TLS 1.3, and enhanced access controls

A centralized Integrations Hub supporting leading wireless infrastructure and enterprise applications, including EHR, MES, nurse call, and other operational systems

Multi-tenant tag roaming for seamless multi-site deployments

Enhanced dashboards, reporting, alert management, and platform performance

Unlike RTLS platforms built around a single positioning technology, Sofia supports Wi-Fi, Bluetooth® Low Energy (BLE), Ultra-Wideband (UWB), infrared (IR), GPS, and RFID within a single platform, allowing organizations to select the right technology for each use case without vendor lock-in. 

Jon Collins, Director of Integrated Product Solutions, AiRISTA: “The latest release of Sofia was built around a simple principle: the platform should improve outcomes, not add complexity. Whether that’s enabling a faster staff duress response, integrating location intelligence with electronic health records (EHRs), manufacturing execution systems (MES), nurse call, or other enterprise applications, or scaling seamlessly across multiple sites, this release removes friction at every layer—for administrators, IT teams, and the frontline staff who rely on Sofia every day. “

Organizations shouldn’t have to replace existing systems to unlock the value of location intelligence. Sofia was designed to integrate with the technologies customers already rely on. The latest release extends that flexibility with a new, centralized Integrations Hub supporting HPE Networking solutions (including HPE Aruba Networking and Juniper Mist), Cisco Spaces, Cisco Meraki, Cisco CMX, and other leading infrastructure platform.

Wyatt Meek, Chief Commercial Officer, AiRISTA: “What we hear consistently from customers evaluating RTLS is that they don’t want to choose between capability and flexibility — they want both. Sofia gives organizations enterprise-grade security and a modernized experience without asking them to give up the freedom to choose the right technology for each use case. That combination is difficult to find elsewhere in this market.”

Sofia is available now. Existing customers can work with their AiRISTA account team to plan upgrades. To learn more, visit www.airistaflow.com.

About AiRISTA

AiRISTA is a leading provider of real-time location systems (RTLS) and location intelligence solutions for healthcare, industrial, and government organizations. Trusted by more than 300 organizations worldwide, the Sofia platform delivers real-time visibility into people, assets, and environments while integrating with a broad ecosystem of wireless infrastructure and enterprise systems. AiRISTA is ISO 9001 and ISO 27001 certified.

View original content to download multimedia:https://www.prnewswire.com/news-releases/airista-launches-newest-version-of-sofia-setting-a-standard-for-enterprise-grade-real-time-location-systems-302830751.html

SOURCE AiRISTA Flow

Continue Reading

Technology

GCG Advisory Partners Reports Strong First-Half 2026, Marked by Four Strategic Acquisitions, $1.1 Billion in New Assets, and Completion of Three-Platform Model

Published

on

By

Firm expands AUM, welcomes new advisory teams, and deepens its national footprint following 2025 recapitalization

CHARLOTTE, N.C., July 21, 2026 /PRNewswire/ — GCG Advisory Partners (“GCG”), a national wealth management aggregator platform, today announced a series of milestones completed in the first half of 2026 that reinforce the firm’s growth trajectory and its position as a partner of choice for independent financial advisors.

Since its August 2025 recapitalization with BharCap Partners, GCG has grown EBITDA by more than 200%, a pace that reflects both a disciplined deal strategy and the caliber of the teams choosing to join. The firm acquires and supports registered investment advisory (RIA) practices nationwide, giving each the infrastructure, capital, and flexibility to keep growing while staying focused on clients.

Completion of the Three-Platform Model

GCG also completed the build-out of its three-platform operating model (independent RIA, broker-dealer/corporate RIA, and hybrid RIA), so advisors can choose the affiliation that best fits their practice and clients. Every prospective partner now has a clear route in, whatever structure they prefer.

Four Acquisitions, Four New Chapters

Gunderson Capital Management. Closed April 3, 2026, this deal added roughly $578 million in AUM, custodied at Charles Schwab, and established GCG’s independent RIA channel. The Mount Pleasant, S.C. firm is led by nationally recognized market commentator Bill Gunderson.

Gateway Capital Advisors. Also effective that day, this $300 million-plus practice joined through an asset purchase, recognized for its entrepreneurial, organically driven growth and deep client-planning work.

Head Investment Partners. In June, this $180 million Knoxville practice joined GCG, led by 30-year advisor Daniel Head and known for its options and risk-management expertise, giving GCG its first footprint in Tennessee.

BlueChip Financial Advisors. A hybrid RIA custodying through Fidelity Institutional Wealth Services, it opened GCG’s first presence in the Northeast and rounded out the firm’s affiliation options, giving incoming teams the full range of ways to join.

Each brings specialized capabilities to GCG’s expanding roster of practices.

Leadership Perspective

“The first half of 2026 has been about disciplined execution: completing our platform, welcoming exceptional advisory teams, and building a firm that advisors and institutional partners alike can trust. We’re proud of what our team has accomplished, and we remain focused on sustainable, high-quality growth, driven by both organic momentum and disciplined acquisitions, through the back half of the year and into 2027.”

— Joel Burris, CEO & Managing Partner, GCG Advisory Partners

Looking Ahead

GCG continues to evaluate new opportunities and remains committed to supporting advisors and clients across all three affiliation models. The firm expects to share further updates later in 2026.

For entrepreneurial advisors looking to build lasting equity in their practice, GCG offers the capital, infrastructure, and partnership to make it happen. To start a confidential conversation, contact our team.

About GCG Advisory Partners

GCG Advisory Partners is a national wealth management aggregator that acquires and supports registered investment advisory practices nationwide. Through its independent RIA, broker-dealer/corporate RIA, and hybrid RIA channels, the firm gives advisors the infrastructure, resources, and flexibility to grow while staying focused on their clients. GCG is backed by BharCap Partners. For more information, visit www.gcgap.com.

Media Contact:

Nicole Caputo
Contact@gcgap.com
704-372-4491

View original content to download multimedia:https://www.prnewswire.com/news-releases/gcg-advisory-partners-reports-strong-first-half-2026–marked-by-four-strategic-acquisitions-1-1-billion-in-new-assets-and-completion-of-three-platform-model-302830173.html

SOURCE GCG Advisory Partners

Continue Reading

Technology

Buzz Health and VetHubRx Partner to Bring Real-Time Prescription Savings to Veterinary Care

Published

on

By

Strategic integration embeds multi-card discount pricing directly into veterinary e-prescribing workflows, expanding affordability and price transparency for pet owners at the pharmacy counter

FORT WALTON BEACH, Fla., July 21, 2026 /PRNewswire/ — Buzz Health™, a healthcare technology company, and VetHubRx, a veterinary e-prescribing platform, today announced a strategic partnership to integrate real-time prescription discount pricing directly into VetHubRx’s e-prescribing and consumer-facing platforms.

Through the collaboration, VetHubRx will embed Buzz Health’s RxCompare® pricing infrastructure into its prescribing workflow, enabling veterinary providers and pet owners to access and apply the lowest available discount price at the point of prescribing and fulfillment. The integration supports automated best-price routing via Buzz Health’s SmartBIN® across a configurable multi-card discount network, delivering real-time price visibility within the digital prescribing experience and seamless claims adjudication through RxCompare’s pharmacy network and infrastructure.

The partnership marks Buzz Health’s first integration with a veterinary e-prescribing platform, extending the company’s prescription affordability technology into a market where most medication purchases are paid entirely out of pocket, given that only 4 to 5% of pets in the U.S. are insured, according to the North American Pet Health Insurance Association.

Unlike human healthcare, pet insurance rarely covers prescription drugs at the point of sale, leaving pet owners fully exposed to retail pricing with limited visibility into available savings. Many pet owners are unaware that the same prescription discount programs available for human medications can also be applied to their pet’s prescriptions, a gap this partnership addresses by embedding savings directly into the prescribing workflow.

“Veterinary prescribing is undergoing a digital transformation, and this partnership positions Buzz Health at the forefront of that shift,” said Lathe Bigler, Senior Vice President, Business Strategy at Buzz Health. “By embedding real-time pricing and multi-card savings directly into the prescribing workflow, we are helping veterinary providers deliver price transparency to pet owners before they arrive at the pharmacy, reducing surprises at the counter and improving prescription fulfillment rates.”

VetHubRx is a standalone e-prescribing application designed for veterinary clinics and animal hospitals, enabling providers to generate and transmit prescriptions electronically to retail pharmacies nationwide. Animal hospitals typically do not dispense medications on-site, meaning prescriptions are mostly routed to retail pharmacies, making real-time pricing visibility at the pharmacy counter particularly valuable. The platform also includes a consumer-facing app that engages pet owners on refills and prescription management.

“Our providers want to give pet owners every advantage when it comes to affording the medications their animals need,” said MJ Hamilton, CEO and Founder of VetHubRx. “Integrating real-time discount pricing into our workflow means pet owners can see the most affordable option at the pharmacy closest to them, all within the same digital experience their veterinarian uses to prescribe. It removes friction from the process and helps ensure prescriptions are filled.”

The partnership focuses on prescriptions for human-equivalent medications commonly prescribed for pets, which are filled at retail pharmacies across the country. The integration applies SmartBIN technology to automatically route each prescription to the discount card offering the lowest available price using a single set of processing codes, ensuring pet owners receive optimal savings with no additional steps required by the prescriber or pharmacist.

Buzz Health currently supports prescription access across thousands of pharmacies nationwide and continues expanding its platform to serve e-prescribing applications, EMR/EHR integrations, and additional enterprise partners.

About Buzz Health

Buzz Health is a healthcare technology company delivering intelligent, customizable prescription solutions through its integrated platforms, including BuzzRx, RxCompare, and RxAffect. Designed for scale and flexibility, Buzz Health’s technology helps streamline pharmacy operations, optimize claims in real time, and improve access and affordability across the prescription ecosystem. By serving as the intelligence layer behind prescription savings and benefit navigation, Buzz Health enables measurable cost reductions, improved adherence, and better health outcomes. Learn more at www.buzzhealth.com.

About VetHubRx

VetHubRx is the first and only e-prescribing platform built exclusively for veterinarians, empowering clinics to electronically prescribe to virtually any participating pharmacy nationwide. By eliminating phone calls, faxes, and unnecessary administrative work, VetHubRx streamlines the prescribing process for veterinary teams while giving pet owners the freedom to fill prescriptions at the pharmacy that best meets their needs. Faster prescribing, greater convenience, and improved access to medications help create a better experience for both clinics and pet owners. Learn more at vethubrx.com.

Media Contact
buzzhealthPR@supremecomms.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/buzz-health-and-vethubrx-partner-to-bring-real-time-prescription-savings-to-veterinary-care-302828773.html

SOURCE Buzz Health

Continue Reading

Trending